Literature DB >> 8311533

The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment.

V Kyle1, B L Hazleman.   

Abstract

OBJECTIVES: To examine the clinical course of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in a prospective study, after the initial two months.
METHODS: Seventy four patients with PMR/GCA were followed for a median of 60 weeks. Detailed clinical and laboratory records were made on each visit.
RESULTS: Twenty per cent of patients with PMR developed GCA and 24% of patients with GCA developed PMR from the onset of symptoms. After two months, most patients experienced at least one relapse. Relapses and persistence of abnormal symptoms and signs were most common in patients with both PMR and GCA and least common in those with GCA alone. Relapses were most common in the first year and 54% occurred in association with steroid reduction. Major complications were rare. Laboratory parameters and temporal artery histology were not helpful in predicting relapse. Only 24% of patients were able to stop steroid treatment after two years.
CONCLUSIONS: Clinicians should consider more frequent review in patients at times of steroid reduction and especially within the first six months of treatment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8311533      PMCID: PMC1005213          DOI: 10.1136/ard.52.12.847

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  17 in total

1.  TEMPORAL ARTERITIS.

Authors:  A G WHITFIELD; M BATEMAN; W T COOKE
Journal:  Br J Ophthalmol       Date:  1963-09       Impact factor: 4.638

2.  Treatment and prognosis in polymyalgia rheumatica and temporal arteritis. A ten-year survey of 53 patients.

Authors:  J von Knorring
Journal:  Acta Med Scand       Date:  1979

3.  Rheumatic polymyalgia. Long-term treatment with steroids.

Authors:  S Paulsen; T O Iversen
Journal:  Acta Rheumatol Scand       Date:  1971

4.  Polymyalgia rheumatica and giant cell arteritis: a seven-year survey.

Authors:  A B Myles
Journal:  Rheumatol Rehabil       Date:  1975-11

5.  Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study.

Authors:  K A Huston; G G Hunder; J T Lie; R H Kennedy; L R Elveback
Journal:  Ann Intern Med       Date:  1978-02       Impact factor: 25.391

6.  Polymyalgia rheumatica syndrome.

Authors:  L Knudsen; G Christensen; L Krohn
Journal:  Scand J Rheumatol       Date:  1982       Impact factor: 3.641

7.  Polymyalgia rheumatica: a 10-year epidemiologic and clinical study.

Authors:  T Y Chuang; G G Hunder; D M Ilstrup; L T Kurland
Journal:  Ann Intern Med       Date:  1982-11       Impact factor: 25.391

8.  Relationship of the erythrocyte sedimentation rate to acute phase proteins in polymyalgia rheumatica and giant cell arteritis.

Authors:  J R Park; J G Jones; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1981-10       Impact factor: 19.103

9.  Giant-cell arteritis, temporal arteritis and polymyalgia rheumatica. A retrospective study of 63 patients.

Authors:  S Sorensen; I Lorenzen
Journal:  Acta Med Scand       Date:  1977

10.  Prognosis and management of polymyalgia rheumatica.

Authors:  J G Jones; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1981-02       Impact factor: 19.103

View more
  14 in total

Review 1.  Giant cell arteritis.

Authors:  J M Calvo-Romero
Journal:  Postgrad Med J       Date:  2003-09       Impact factor: 2.401

Review 2.  Best practice in primary care pathology: review 2.

Authors:  W S Smellie; J O Forth; C A M McNulty; L Hirschowitz; D Lilic; R Gosling; D Bareford; E Logan; K G Kerr; G P Spickett; J Hoffman; A Galloway; C A Bloxham
Journal:  J Clin Pathol       Date:  2006-02       Impact factor: 3.411

Review 3.  Polymyalgia rheumatica.

Authors:  Clement J Michet; Eric L Matteson
Journal:  BMJ       Date:  2008-04-05

4.  Comparable Rates of Glucocorticoid-Associated Adverse Events in Patients With Polymyalgia Rheumatica and Comorbidities in the General Population.

Authors:  Izzat Shbeeb; Divya Challah; Shafay Raheel; Cynthia S Crowson; Eric L Matteson
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-02-22       Impact factor: 4.794

Review 5.  Polymyalgia rheumatica: strategies for efficient practice and quality assurance.

Authors:  Michael Schirmer; Christian Dejaco; Bhaskar Dasgupta; Eric L Matteson
Journal:  Rheumatol Int       Date:  2015-06-02       Impact factor: 2.631

6.  Glucocorticoid usage in giant cell arteritis over six decades (1950 to 2009).

Authors:  A Chandran; Pr D Udayakumar; T A Kermani; K J Warrington; C S Crowson; E L Matteson
Journal:  Clin Exp Rheumatol       Date:  2015-05-26       Impact factor: 4.473

7.  Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?

Authors:  M J van der Veen; H J Dinant; C van Booma-Frankfort; G A van Albada-Kuipers; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  1996-04       Impact factor: 19.103

8.  Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR).

Authors:  Jung Hwa Lee; Sang Tae Choi; Jin Su Kim; Bo Young Yoon; Seung-Ki Kwok; Hyun-Sook Kim; Yun Sung Kim; Jung-Soo Song; Sang-Heon Lee; Hae-Rim Kim
Journal:  Rheumatol Int       Date:  2012-11-27       Impact factor: 2.631

Review 9.  Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus.

Authors:  Christian Dejaco; Christina Duftner; Marco A Cimmino; Bhaskar Dasgupta; Carlo Salvarani; Cynthia S Crowson; Hilal Maradit-Kremers; Andrew Hutchings; Eric L Matteson; Michael Schirmer
Journal:  Ann Rheum Dis       Date:  2010-11-19       Impact factor: 19.103

10.  2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.

Authors:  Bhaskar Dasgupta; Marco A Cimmino; Hilal Maradit-Kremers; Wolfgang A Schmidt; Michael Schirmer; Carlo Salvarani; Artur Bachta; Christian Dejaco; Christina Duftner; Hanne Slott Jensen; Pierre Duhaut; Gyula Poór; Novák Pál Kaposi; Peter Mandl; Peter V Balint; Zsuzsa Schmidt; Annamaria Iagnocco; Carlotta Nannini; Fabrizio Cantini; Pierluigi Macchioni; Nicolò Pipitone; Montserrat Del Amo; Georgina Espígol-Frigolé; Maria C Cid; Víctor M Martínez-Taboada; Elisabeth Nordborg; Haner Direskeneli; Sibel Zehra Aydin; Khalid Ahmed; Brian Hazleman; Barbara Silverman; Colin Pease; Richard J Wakefield; Raashid Luqmani; Andy Abril; Clement J Michet; Ralph Marcus; Neil J Gonter; Mehrdad Maz; Rickey E Carter; Cynthia S Crowson; Eric L Matteson
Journal:  Ann Rheum Dis       Date:  2012-04       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.